CYP4Z1 is a cytochrome P450 monooxygenase that catalyzes the in-chain oxidation of fatty acids through hydroxylation and epoxidation reactions 1. The enzyme hydroxylates lauric and myristic acids predominantly at omega-4 and omega-2 positions, respectively 1, and catalyzes stereoselective epoxidation of polyunsaturated fatty acids to produce bioactive lipid metabolites like 20-hydroxyeicosatetraenoic acid (20-HETE) 2. Mechanistically, CYP4Z1 uses molecular oxygen and NADPH via cytochrome P450 reductase to insert one oxygen atom into substrates 1. CYP4Z1 is uniquely overexpressed in breast cancer and associated with poor prognosis 2, with expression also detected in ovarian, lung, and prostate cancers 3. In breast tissue, CYP4Z1 expression is preferentially regulated by glucocorticoid and progesterone receptors 4. Functionally, CYP4Z1 overexpression promotes tumor angiogenesis and growth by increasing vascular endothelial growth factor (VEGF)-A production and decreasing tissue inhibitor of metalloproteinase-2 (TIMP-2) through PI3K/Akt and ERK1/2 pathway activation 2. High CYP4Z1 expression independently correlates with reduced patient survival in ovarian cancer 5. These characteristics make CYP4Z1 a promising therapeutic target for cancer treatment through selective enzyme inhibition or prodrug activation strategies 6.